Excerpts from the NHLBI revised Guidelines for the Diagnosis and Management of Asthma include:
 
- “FeNO may be useful for monitoring response to asthma treatment”, pg 42
- “FeNO may be used in diagnosing asthma”, pg 62, 68, 89
-  Markers “could be useful in guiding treatment selection”, pg 62, 68, 89
-  Markers “may allow accurate estimation of the risk of future adverse events”, pg 67
 
Statements that are general regarding biomarkers are as follows:
- “Once these “biomarker” tools are refined for application to the clinical setting, they could be useful in guiding treatment selection to achieve and monitor asthma control quickly.” pg 62, 68, 89
- “Few studies have validated or anchored assessment of biomarkers by analyzing their relationship to the rate of adverse events or decline in pulmonary function over time.” pg 67
- “FeNO and sputum may also be useful, but they require further evaluation in both children and adults before they can be recommended as clinical tools for routine asthma management.”  pg 76